The Gavathiotis laboratory's research aims to elucidate and target molecular signaling mechanisms of cell death and cell surivival that are deregulated in cancer and other diseases. Our goal is to translate structural and mechanistic insights into novel pharmacologic strategies and prototype therapeutics that can lead to cures. To achieve our goal, we take an interdisciplinary approach using chemical synthesis, structure-based design, structural biology, biochemistry, cellular and in vivo pharmacology.
Tom identified a new binding site on BAX that controls BAX inhibition from the BCL-2 BH4 helix in a recent collaborative paper published in Molecular Cell!
Dr. Gavathiotis was awarded the 2014 Young Chemical Biologist Award and gave a podium presentation during the Rising Stars of Chemical Biology Session in the 3rd Annual Conference of the International Chemical Biology Society
Two papers in the European Journal of Medicinal Chemistry and Marine Drugs report our collaborative efforts to identify Mcl-1 selective inhibitors and dual Mcl-1/Bcl-xL inhibitors based on the marinopyrole scaffold.
Dr. Gavathiotis was awarded a $1.73 million R01 grant to investigate a novel pharmacological strategy for killing cancer cells by activating the protein BAX—a key player in apoptosis, the process by which cells self-destruct. BAX performs its deadly work by puncturing the membranes of mitochondria, the energy power plants inside cells. See more
The Innovation core is funded through a National Institute of Aging PO1 Award led by Dr. Ana Maria Cuervo. Our lab will provide expertise, reagents, analysis and interpretation using chemical and structural biology technologies with the aim to assist the development of pharmacological modulation of key components of autophagy in aging.
Onyi received a prestigious F31 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship by NIH. Congrats Onyi!
Denis Reyna was accepted to the Einstein Graduate Program in Biomedical Sciences. Congrats Denis!